On May 13, 2020, Arvinas, Inc. (the “Company”) announced updated safety and initial efficacy data contained in an abstract scheduled as an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29–31, 2020. The presentation will share updated data from the dose escalation portion of the Company’s Phase 1/2 clinical trial of ARV-110 in men with metastatic castration-resistant prostate cancer. The abstract describes two patients with ongoing confirmed prostate-specific antigen responses, including one with an unconfirmed partial tumor response.

The presentation will include data collected since the abstract submission date. Dose escalation for the Phase 1/2 clinical trial continues, supported by the safety profile to date, with enrollment initiated above the previously disclosed daily dose of 280 milligrams.

Abstract details are as follows:

Presentation Title: First-in-human phase I study of ARV-110, an androgen receptor PROTAC degrader in patients with metastatic castrate-resistant prostate cancer following enzalutamide and/or abiraterone.

Abstract Number: 3500

Session Type: Oral Abstract Session

Session Track: Development Therapeutics – Molecularly Targeted Agents and Tumor Biology

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of the Company’s product candidates, the conduct of and plans for the Company’s ongoing Phase 1/2 clinical trial for ARV-110, the plans for presentation of data from the Company’s clinical trial for ARV-110 and the potential advantages and therapeutic potential of the Company’s product candidates. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including but not limited to: whether the Company will be able to successfully conduct Phase 1/2 clinical trials for ARV-110 and ARV-471, complete its clinical trials for its product candidates, and receive results from its clinical trials on the Company’s expected timelines, or at all, whether the Company’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s expected timeline and other important factors discussed in the “Risk Factors” sections contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this Current Report on Form 8-K reflect the Company’s current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K.